FDA Fast-Tracks Review of 3 New Immunotherapy Options for Esophageal Cancer Patients
The U.S. Food & Drug Administration has granted Priority Review for the use of immunotherapies in three new designations for [...]
New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
Latest US Stats Show More Esophageal Cancer Cases, Fewer Deaths
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
Hope is Important
These are challenging times. And we at ECAN are keeping our focus trained on the positive difference we can [...]
2020 Wins for Esophageal Cancer Patients
Despite the challenges of 2020, progress was achieved in the battle to end Esophageal Cancer - much of it thanks [...]
Make It A Life-Saving Birthday
In May of 2010, Brent Sharpless was in the prime of his life. He was an active, healthy 36-year-old who [...]
Groundbreaking Immunotherapy Studies in Esophageal Cancer show Significant Benefits
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
Personalized Approach Shows Survival Benefit in Esophageal Adenocarcinoma
Results of a clinical study called PANGEA (Personalized ANtibodies for GastroEsophageal Adenocarcinoma) found survival benefits for patients when compared to [...]
Best Birthday Gift
A message from ECAN's founder: My husband’s birthday came this week. And this year, for the first time since he [...]
Immunotherapy Breakthroughs for Esophageal Cancer Patients
The early results of two large, Phase III clinical trials of the immunotherapy Opdivo (nivolumab) showed significant survival benefits for [...]